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Abstract: Infection caused by hepatitis B virus (HBV) can be prevented through a safe and effective
vaccine. This study analysed the kinetics of serum antibodies against hepatitis B surface antigen
(HBsAg) (anti-HBs) titers in relation to previous vaccine boosters in Italian nursing students who were
followed up for two years. Serum anti-HBs titers were evaluated at the first visit, after vaccine booster
(if required) and at visit after two years. Overall, 483 students (mean age = 21.7 years; SD = 3.7) with
median anti-HBs IgG titer of 6 mUI/mL (interquartile range (IQR) = 0–34) were enrolled. A total of
254 (52.5%) students with a titer lower than 10 mIU/mL were offered an anti-HBV booster at the first
visit. Among these students, an exponential relation between anti-HBs IgG titer, one month after HBV
booster and anti-HBs IgG titer two years later was found (y = 3.32 exp (0.0045x); R2 = 0.48; p < 0.001).
Students with anti-HBV titer higher than 10 mIU/mL (N = 229) were followed up, and anti-HBs IgG
titers at follow-up visit linearly correlated with anti-HBV baseline titers (y = 0.86x + 26.2; R2 = 0.67;
p < 0.001). A decrease in anti-HBs titers can be expected a few years after the anti-HBV booster dose.
This reduction is more pronounced than that observed in students not administered the booster dose
and is exponential with respect to basal titers assessed after the booster dose.
Keywords: hepatitis B virus (HBV); occupational visit; HCWs health; persistence of protection;
vaccine booster; anamnestic response
1. Introduction
Hepatitis B virus (HBV) is a double-stranded DNA virus that belongs to the Hepadnavirus family.
It has been classified into 10 genotypes (A–J) and more than 40 sub-genotypes [1,2].
Although HBV is a vaccine-preventable disease, it is still one of the most common infectious viral
diseases worldwide. It has a different degree of endemicity, evaluated based on the seroprevalence of
the hepatitis B surface antigen (HBsAg), and ranges from >8% (high endemicity) to 2–8% (intermediate
endemicity) and <2% (low endemicity) [3]. In the European region, it has been estimated that about
1.6% of the population is infected [4].
HBV burden is not negligible; in fact, in 2015 approximately 257 million people were living with
chronic HBV infection and 887,000 died worldwide because of the disease or its clinical complications [5].
The virus is transmitted by activities involving percutaneous or mucosal contact with blood and
other body fluids of the infected person, potentially even by indirect contact, as the virus can remain
viable outside the human body, even for several months [6,7].
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Perinatal or vertical transmission to newborns is also possible and appears to be the most important
factor in determining the high prevalence in endemic areas [8].
The natural history of the disease ranges from asymptomatic presentations to life-threatening
illnesses such as acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma [9,10].
A vaccine against HBV has been available since 1981, and Italy was one of the first countries
to introduce mandatory universal vaccination for newborns and 12-year-old adolescents in 1991 as
well as adults belonging to high-risk groups [11]. The vaccination of adolescents was stopped in
2004, while the immunization of newborns was maintained, resulting in 24 cohorts of subjects being
immunized against HBV in 12 years [11,12].
Healthcare workers (HCWs) are the group most at risk of infection and, for this reason, according to
the Italian national vaccination plan, it is essential to vaccinate them before they start work activity [13].
According to these considerations, serum antibodies against HBsAg (anti-HBs) can be evaluated
to check immunity in HCWs, including students who attend medical university courses [14,15]. A titer
higher than 10 mIU/mL is generally considered a threshold to be protected against the infection, but a
possible decline in the antibody levels has been observed [16,17].
However, there is a common agreement that a responder to the primary dose should be considered
protected despite the actual antibody titer [6]. In the past several years, the international scientific
community has raised a debate about the need for a booster dose [18].
It is clear that there is a need for more studies to increase the knowledge about HBV vaccination,
including from an immunological point of view. To reduce this lack of knowledge, the main aim of the
present study was to evaluate anti-HBs titers in a sample of university nursing students followed up
for two years, assessing the role of anti-HBV booster in relation to the time to decay of anti-HBs titers.
2. Materials and Methods
An observational study was carried out by considering 637 students who, from November
2015 to April 2020, attended the nursing school at the University of Palermo, Italy. Students were
examined during their first and third academic years in order to evaluate occupational risks. For each
student, a standardized form was filled out with information regarding sociodemographic variables
(age, gender, country of origin), personal anamnesis (relatives’ diseases and personal remote and
proximate pathologies), and previous HBV vaccinations (at infancy or adolescence).
Moreover, a medical examination was performed, and a blood sample was obtained to evaluate
serum HBsAg, anti-HBs, and anti-HBc. All students were negative for anti-HBc, and those who were
negative for HBsAg and with anti-HBs titers lower than 10 mIU/mL were subsequently boosted and the
titer was reassessed after one month. All enrolled nursing students were previously vaccinated against
HBV, they were HBsAg negative, and none of them received a vaccine booster before the enrolment.
All students with a titer ≤10 mIU/mL at the first visit were boosted within one month, after they
had produced the vaccination booklet. A minority of students who were not able to produce this
documentation were asked to obtain a vaccine certification by the Local Health Unit and were vaccinated
only after the acquisition of such certification.
Only students who met the following inclusion criteria were considered in the analyses:
1. Those who attended both occupational visits in the first and third years.
2. Those who underwent all laboratory analyses (in the first year, after HBV booster if required,
and in the third year).
As 154 students did not meet the inclusion criteria, they were excluded from the analyses.
Thus, analyses were finally carried out on a total of 483 (75.8% of the initial sample) students.
In accordance with Italian law, written informed consent was obtained from all subjects.
The study was approved by the Ethics Committee of the University Hospital “P. Giaccone” of
Palermo (Protocol number 26/2016, 19 October 2016).
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2.1. Serological Tests
Serological analyses were performed using commercial chemiluminescence assays (VITROS
anti-HBs assay on the VITROS ECI Immunodiagnostic System, Ortho-Clinical Diagnostics,
High Wycombe, UK). The anti-HBs level was expressed as mIU/mL. Anti-HBs titers higher than
10 mIU/mL were considered as cut-off for statistical analyses, whereas those below 4.23 mIU/mL
(the limit of detection of the assay) in the analyses were computed as 0 (undetectable).
2.2. Statistical Analysis
Absolute and relative frequencies were calculated for the categorical (qualitative) variables,
and normally distributed quantitative variables were summarized by their means (standard deviations).
The differences in the categorical variables were analysed using chi-squared tests (or Fisher’s exact test,
when appropriate).
Means or medians were compared using either Student’s t-test or Wilcoxon rank sum test.
To evaluate potential confounders due to sex and birth cohort, these last variables were included in
two multivariate regression models, and subsequently excluded if not significantly associated with the
level of anti-HBs.
The Akaike information criterion (AIC) was used to assess the fitting function of the different
models. All information was entered into a database created with Excel 10.0 (Microsoft, Redmond,
Seattle, WA, USA). All data were analysed using the R statistical software.
3. Results
Figure 1 describes the flow-chart diagram of the study. A total of 483 nursing students were
considered in the analyses, 323 (66.9%) of whom were female (M:F ratio = 0.49). The mean age at
first visit was 21.7 years (SD = 3.7), and all students were born between 1966 and 1999. As reported
in Table 1, median anti-HBs IgG titer was 6 mIU/mL (interquartile range (IQR) = 0–34 mIU/mL),
whereas the median was 41 mIU/mL (IQR = 18–123 mIU/mL) among 229 students with anti-HBs IgG
titers above 10 mIU/mL. Statistically significantly higher levels were found in students vaccinated at
adolescence (50 vs. 0 mIU/mL among those vaccinated at infancy, p < 0.001).
Table 1. General characteristics of nursing students in relation to the median of serum antibodies against
hepatitis B surface antigen (anti-HBs) IgG titers at the first visit.
Variable N (%) Median Anti HBs IgG Titer at First Visit (mIU/mL) (IQR)
Sex
Male 160 (33.1) 8 (0–43)
Female 323 (66.9) 0 (0–28)
Birth cohort
1992 or less 101 (20.9) 38 (3–174)
1993–1994 84 (17.4) 0 (0–22)
1995–1996 198 (41.0) 0 (0–17)
>1997 100 (20.7) 6 (0–18)
Vaccination timing
At adolescence 85 (17.6) 50 (8–219)
At infancy 398 (82.4) 0 (0–19)
Booster after first
visit
Yes 254 (52.6) 0 (0–0)
No 229 (47.4) 36 (16–105)
Total 483 (100) 6 (0–34)
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students; black boxes: phase of the study).
A total of 254 (52.5%) students had a titer below 10 mIU/mL and 185 of them (72.8%) had no
detectable levels of antibodies. These students were boosted at the first occupational visit. In a
multivariable logistic regression model, anti-HBV titers >1000 mIU/mL one month after HBV booster
were found to b assoc at d with h gher anti-HBV basal titers (p < 0.001).
Among students requiring vaccine boosters, 22 (8.6%) were vaccinated during adolescence. In this
group, vaccine boosting determined higher anti-HBV titers (median = 1000 mIU/mL; IQR 470–1000)
than in those vaccinated at infancy (median = 554 mIU/mL; IQR = 108–1000), although this difference
was not statistically significant (p = 0.08).
As shown in Figure 2, a statistically significant correlation was found between anti-HBs IgG titers
one month after HBV booster and anti-HBs IgG titers two years later (at the third-year visit) among
students administered boosters (function y = 3.32 exp (0.0045x); R2 = 0.48; p < 0.001).
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Figure 2. Correlation analysis between anti-HBs titers one month after hepatitis B virus (HBV) booster
dose and anti-HBs titers two years later (R2 = 0.48; p < 0.001).
To evaluate the potential confounding factors, sex and birth cohort were initially included in
a multivariable regression analysis. However, these were subsequently excluded as they were not
statistically significantly associated with anti-HBs IgG titers at the third-year visit and did not improve
the overall fit ing of the model.
Students with anti-HBV titer higher than 10 mIU/mL (N = 229) were only monitored during the
two-year follow-up period. As reported in Figure 3, in these students anti-HBs IgG titers at two-year
follow-up were linearly correlated with anti-HBV baseline titers (function y = 0.86x + 26.2; R2 = 0.67;
p < 0.001).
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In Table 2, starting anti-HBs titers were compared with anti-HBs titers <10 mIU/mL at the two-year
follow-up visit, and were stratified according to their anti-HBV booster status. A higher percentage
of students who received the booster reported anti-HBs titers <10 mIU/mL after two years (18.1% vs.
14.4%), and this difference was statistically significant when considering only students with starting
titers between 10 and 100 mIU/mL (55.7% vs. 17.9%; p < 0.001).
Table 2. Relative frequencies of students with hepatitis B surface antibody (anti-HBs) titers <10 mIU/mL at
2-year follow-up visit, stratified according to their basal value and anti-hepatitis B virus (HBV) boostering.
Starting Anti-HBs Titers
Baseline * Value (mIU/mL)





0–100 34/61 (55.7%) 30/168 (17.9%) <0.001
101–200 5/20 (25%) 2/24 (8.3%) 0.24
201–300 2/16 (12.5%) 0/15 (0%) 0.49
301–400 2/5 (40%) 0/2 (0%) 1
>400 3/149 (2%) 1/17 (5.9%) 0.34
Total 46/254 (18.1%) 33/229 (14.4%) 0.39
* For boosted students, the starting anti-HBs titer was considered after boosting.
Finally, Figure 4 shows the modelled values obtained using the mathematical functions with
the best fit between levels of anti-HBs titers, after two-year follow-up, in students who received and
did not receive a booster vaccination. Students who had received a booster vaccination showed an
exponential reduction in anti-HBs titers after the two-year follow-up, whereas those who did not
receive the booster showed a linear reduction.Vaccines 2020, 8, x 7 of 11 
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4. Discussion
Healthcare workers have the highest estimated infection rate for HBV [19]. Therefore, it is
crucial that they obtain a proper occupational risk assessment before starting work activity to protect
themselves and patients.
It is well documented that after primary HBV immunization, anti-HBs concentrations slowly
decline and about 15–50% of vaccinated children will have low or undetectable concentrations of
anti-HBs 5–15 years after vaccination [18].
At the same time, about 30–60% of adults vaccinated against HBV will have anti-HBs concentrations
decline to <10 mIU/mL within 9–11 years [20].
Data obtained in the present study are consistent with these findings; more than half (52.5%) of
the analysed students had titers <10 mIU/mL.
According to previously published investigations, this percentage was higher among students
vaccinated at infancy who also had lower median anti-HBV titers [21].
Furthermore, in our study, the percentage of students with titers <10 mIU/mL was relatively
higher than that found in other studies that evaluated medical students in Italy (40.8%, 29.3%, 12%,
15.8%) and lower with respect to that in other countries (72.4% in Malaysia, 59% in Israel) [22–26].
However, we can suppose that these percentages are strictly related to the greater number of
years since the primary vaccination cycle (about two decades before) as well as the time of vaccination,
as vaccination during infancy (86% of our students) is usually associated with a shorter immunity
persistence [27,28].
When assessing healthcare students at the occupational visit, one major priority is to evaluate
the effective immunization status after the initial HBV vaccination series. In the past several decades,
several international guidelines have recommended that, after HBV vaccination, an anti-HBs serologic
test result of >10 mIU/mL indicates immunity and, therefore no further routine doses or testing should
be required [29,30].
In particular, these recommendations are consistent with the findings that, despite a decline in
anti-HBs titers is expected over time, protection persisted, and vaccinated subjects with serologic
evidence of HBV infection did not develop clinically significant sequelae [31–35]. It is noteworthy that
about 38% of our students had no detectable anti-HBs titers and, thus, it can be assumed there was no
response to the primary vaccination cycle. For this reason and consistent with the Centers for Disease
Control and Prevention (CDC) recommendations, anti-HBs testing was performed for all students
upon admission to medical school if a recent protective titer was not available. All students with
anti-HBs titers <10 mIU/mL were thus administered a booster dose, and the large majority responded
to the vaccination with a considerable increase in the anti-HBs titer after 1 month, as reported in nearly
all other studies [24,36,37].
This finding suggests that a high proportion of vaccine recipients retain immune memory and
would develop an anti-HBs response on exposure to HBV. As a second point of interest, we observed
a good correlation between pre- and post-booster anti-HBs levels, contrary to a study carried out in
Saudi Arabia, where the correlation was not significant [38].
Moreover, we analyzed the persistence of anti-HBs titers over time in boosted and not-boosted
students. Some international studies have found that a major predictor of anti-HBs protective titers is
the peak level of anti-HBs immediately achieved after primary immunization [39]. In other words,
the higher the vaccine-induced anti-HBs concentration after the primary vaccination course, the longer
the antibodies will persist. This finding is also probably true after booster doses. Moreover, our results
confirm that these latter levels are well correlated with anti-HBs titers measured two years later.
However, anti-HBs titers appear to have different kinetics in boosted and not-boosted subjects, with a
rapid decay among the boosted subjects.
These different kinetics may not have a real impact from a clinical point of view, as it is expected
that all subjects will be similarly protected against chronic active hepatitis. However, we believe that it
is important to study these different expected anti-HBs titers for two main reasons.
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First, clinicians need to know that boosted subjects can rapidly reduce their anti-HBs titers without
the need for a further booster dose, especially in a shorter period. Second, very low anti-HBs titers could
be protective against chronic active hepatitis but not against HBV infection. This last consideration
may also have some public health implications in terms of spreading of the virus.
Finally, we have to highlight that our study unfortunately did not change the management of
healthcare workers and, according to international guidelines, if they have anti-HBs titers <10 mmIU/mL
and no evidence of a previous response to primary vaccination cycle, they have to be boosted. However,
our findings change the knowledge about what occupational physicians can expect after boosting, as in
a majority of boosted subjects, a very rapid decrement in anti-HBs titers can be observed after boosting.
5. Conclusions
The present study has some limitations. In particular, we analysed a relatively small sample size
and this could be responsible for the low precision in the estimates and type II errors. We cannot
exclude that we analysed some students who did not respond to the first vaccination cycle.
Moreover, a two-year follow-up could be a short period for assessing the long-term persistence
of antibodies, especially considering that our sample could be affected by a selection bias due to the
exclusive recruitment of young adults and without any evidence of abnormalities in the haemochrom.
Thus, it is possible that the observed kinetics are not representative of and generalizable to the
entire general population, including those with chronic health problems. Finally, for a small number
of students, there was no evidence that they had completed the primary vaccination cycle and,
although they had anti-HBs titers above 10 mIU/mL, it is not possible to exclude a role of this factor in
our results.
Despite these limitations, our study suggests that an important decrease in anti-HBs titers can be
expected just a few years after anti-HBV booster in a relatively high percentage of boosted subjects.
This reduction is quantitatively more pronounced than that observed in not-boosted students,
and is exponential with respect to basal titers assessed after booster vaccination.
Further long-term follow-up studies will be required to explore in depth the relationship between
HBV vaccination, booster, and duration of anti-HBV immunity. Moreover, evaluating the occurrence of
anti-HBc in boosted students versus those with higher anti-HBs levels could help to assess if boosting
increases the protection against HBV infection or the development of chronic infection.
Finally, it will be necessary to clarify how long immune memory persists and whether booster
doses may still be needed in the long term to guarantee lifetime protection.
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